IUC26692-90 Benchmarking Artificial Intelligence-Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer
AI models show moderate-to-good discrimination for ICI response and OS prognosis in BLCA, but evidence is constrained by reliance on a single trial cohort (IMvigor210) and training cohort (TCGA-BLCA), with internal and external OS validation each corroborated by only one study, limiting generalisability.